- 1D
- 5D
- 1M
- 6M
- 1Y
- 5Y
Price Range
- 1D
- 5D
- 1M
- 6M
- 1Y
- 5Y
Price Range
Key Metrics
- Market Cap (In Cr) 8889.73
- Beta 0.57
- Div. Yield (%) 0.36
- P/B 1.84
- TTM P/E 32.14
- Peg Ratio 2.01
- Sector P/E 18.66
- D/E -
- Open Price 0
- Prev Close 1396.7
Analysis
-
1 Week-3.24%
-
3 Months-20.45%
-
6 Month-12.31%
-
YTD-7.28%
-
1 Year-16.94%
- 21% Low risk
- 21% Moderate risk
- 21% Balanced Risk
- 21% High risk
- 21% Extreme risk
8 Analysts
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
- Ratings
- Current
- Strong Sell
- 0
- Sell
- 0
- Hold
- 0
- Buy
- 3
- Strong Buy
- 5
Zydus Wellness News
Stocks to Watch: Dr Reddy’s, Maruti, Hero Moto, HDFC, Bandhan Bank, InterGlobe
2 min read . 10 May 2021PPFAS Mutual Fund removes Zydus Wellness from flexi cap, tax saver funds
1 min read . 13 Apr 2021Top stocks for Diwali 2020 : ICICI Sec's five Muhurat picks, up to 30% upside
2 min read . 05 Nov 2020Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2022
- Total Revenue
- 2009.1
- Selling/ General/ Admin Expenses Total
- 627.45
- Depreciation/ Amortization
- 23.62
- Other Operating Expenses Total
- 18.08
- Total Operating Expense
- 1687.09
- Operating Income
- 322.01
- Net Income Before Taxes
- 306.02
- Net Income
- 308.87
- Diluted Normalized EPS
- 48.54
- Period
- 2022
- Total Assets
- 5692.18
- Total Liabilities
- 848.15
- Total Equity
- 4844.03
- Tangible Book Valueper Share Common Eq
- 59.49
- Period
- 2022
- Cashfrom Operating Activities
- 236.85
- Cashfrom Investing Activities
- -58.93
- Cashfrom Financing Activities
- -233.82
- Net Changein Cash
- -55.9
- Period
- 2021
- Total Revenue
- 1866.67
- Selling/ General/ Admin Expenses Total
- 624.28
- Depreciation/ Amortization
- 25.16
- Other Operating Expenses Total
- 21.84
- Total Operating Expense
- 1679.6
- Operating Income
- 187.07
- Net Income Before Taxes
- 112.21
- Net Income
- 118.73
- Diluted Normalized EPS
- 33.69
- Period
- 2021
- Total Assets
- 5666.43
- Total Liabilities
- 1098.64
- Total Equity
- 4567.79
- Tangible Book Valueper Share Common Eq
- 15.71
- Period
- 2021
- Cashfrom Operating Activities
- 286.73
- Cashfrom Investing Activities
- -10.41
- Cashfrom Financing Activities
- -216.43
- Net Changein Cash
- 59.89
- Period
- 2020
- Total Revenue
- 1766.82
- Selling/ General/ Admin Expenses Total
- 615.03
- Depreciation/ Amortization
- 26.39
- Other Operating Expenses Total
- 20.97
- Total Operating Expense
- 1516.33
- Operating Income
- 250.49
- Net Income Before Taxes
- 121.27
- Net Income
- 141.72
- Diluted Normalized EPS
- 29.56
- Period
- 2020
- Total Assets
- 5589.68
- Total Liabilities
- 2129.02
- Total Equity
- 3460.66
- Tangible Book Valueper Share Common Eq
- -174.84
- Period
- 2020
- Cashfrom Operating Activities
- 259.25
- Cashfrom Investing Activities
- -17.12
- Cashfrom Financing Activities
- -259.69
- Net Changein Cash
- -17.56
- Period
- 2019
- Total Revenue
- 842.38
- Selling/ General/ Admin Expenses Total
- 340.54
- Depreciation/ Amortization
- 12.51
- Other Operating Expenses Total
- 18.14
- Total Operating Expense
- 680.98
- Operating Income
- 161.4
- Net Income Before Taxes
- 170.63
- Net Income
- 169.14
- Diluted Normalized EPS
- 40.1
- Period
- 2019
- Total Assets
- 5458.52
- Total Liabilities
- 2072.24
- Total Equity
- 3386.28
- Tangible Book Valueper Share Common Eq
- -168.86
- Period
- 2019
- Cashfrom Operating Activities
- 218.68
- Cashfrom Investing Activities
- -4161.65
- Cashfrom Financing Activities
- 4051.53
- Net Changein Cash
- 108.56
- Period
- 2018
- Total Revenue
- 521.02
- Selling/ General/ Admin Expenses Total
- 209.62
- Depreciation/ Amortization
- 8.88
- Other Operating Expenses Total
- 9.65
- Total Operating Expense
- 404.74
- Operating Income
- 116.28
- Net Income Before Taxes
- 149.74
- Net Income
- 133.9
- Diluted Normalized EPS
- 34.27
- Period
- 2018
- Total Assets
- 828.93
- Total Liabilities
- 137.74
- Total Equity
- 691.19
- Tangible Book Valueper Share Common Eq
- 171.02
- Period
- 2018
- Cashfrom Operating Activities
- 69.06
- Cashfrom Investing Activities
- -59.12
- Cashfrom Financing Activities
- -1.82
- Net Changein Cash
- 8.12
- Period
- 2017
- Total Revenue
- 462.36
- Selling/ General/ Admin Expenses Total
- 183.09
- Depreciation/ Amortization
- 7.16
- Other Operating Expenses Total
- 9.67
- Total Operating Expense
- 370.46
- Operating Income
- 91.9
- Net Income Before Taxes
- 124
- Net Income
- 108.98
- Diluted Normalized EPS
- 27.93
- Period
- 2017
- Total Assets
- 683.17
- Total Liabilities
- 125.98
- Total Equity
- 557.19
- Tangible Book Valueper Share Common Eq
- 136.7
- Period
- 2017
- Cashfrom Operating Activities
- 76.95
- Cashfrom Investing Activities
- -72.05
- Cashfrom Financing Activities
- -6.21
- Net Changein Cash
- -1.31
- Period
- 2022-12-31
- Total Revenue
- 415.58
- Selling/ General/ Admin Expenses Total
- 79.35
- Depreciation/ Amortization
- 5.88
- Other Operating Expenses Total
- 74.8
- Total Operating Expense
- 393.27
- Operating Income
- 22.31
- Net Income Before Taxes
- 19.31
- Net Income
- 19.56
- Diluted Normalized EPS
- 3.07
- Period
- 2022-12-31
- Period
- 2022-12-31
- Period
- 2022-09-30
- Total Revenue
- 429.47
- Selling/ General/ Admin Expenses Total
- 95.32
- Depreciation/ Amortization
- 6.43
- Other Operating Expenses Total
- 74.4
- Total Operating Expense
- 419.64
- Operating Income
- 9.83
- Net Income Before Taxes
- 8.24
- Net Income
- 8.47
- Diluted Normalized EPS
- 1.33
- Period
- 2022-09-30
- Total Assets
- 5504.25
- Total Liabilities
- 546.7
- Total Equity
- 4957.55
- Tangible Book Valueper Share Common Eq
- 77.6
- Period
- 2022-09-30
- Cashfrom Operating Activities
- 112.05
- Cashfrom Investing Activities
- -13.28
- Cashfrom Financing Activities
- -211.48
- Net Changein Cash
- -112.71
- Period
- 2022-06-30
- Total Revenue
- 696.76
- Selling/ General/ Admin Expenses Total
- 141.26
- Depreciation/ Amortization
- 6.04
- Other Operating Expenses Total
- 88.77
- Total Operating Expense
- 557.59
- Operating Income
- 139.17
- Net Income Before Taxes
- 136.98
- Net Income
- 137.01
- Diluted Normalized EPS
- 21.83
- Period
- 2022-06-30
- Period
- 2022-06-30
- Period
- 2022-03-31
- Total Revenue
- 639.78
- Selling/ General/ Admin Expenses Total
- 104.91
- Depreciation/ Amortization
- 6.08
- Other Operating Expenses Total
- 78.95
- Total Operating Expense
- 504.36
- Operating Income
- 135.42
- Net Income Before Taxes
- 131.4
- Net Income
- 133.3
- Diluted Normalized EPS
- 20.95
- Period
- 2022-03-31
- Total Assets
- 5692.18
- Total Liabilities
- 848.15
- Total Equity
- 4844.03
- Tangible Book Valueper Share Common Eq
- 59.49
- Period
- 2022-03-31
- Cashfrom Operating Activities
- 236.85
- Cashfrom Investing Activities
- -58.93
- Cashfrom Financing Activities
- -233.82
- Net Changein Cash
- -55.9
- Period
- 2021-12-31
- Total Revenue
- 388.09
- Selling/ General/ Admin Expenses Total
- 91.37
- Depreciation/ Amortization
- 5.84
- Other Operating Expenses Total
- 63.7
- Total Operating Expense
- 361.64
- Operating Income
- 26.45
- Net Income Before Taxes
- 22.72
- Net Income
- 23.3
- Diluted Normalized EPS
- 3.66
- Period
- 2021-12-31
- Period
- 2021-12-31
Forecast
Forecast
Forecast
Technical
- 5 Day1411.3
- 10 Day1429.3
- 20 Day1459.52
- 50 Day1523.92
- 100 Day1593.65
- 300 Day1599.24
Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- KRBL
- 397.2
- 1.95
- 0.49
- 449.4
- 184.85
- 9360.28
- Eid Parry India
- 525.25
- -10.6
- -1.98
- 673.3
- 386.05
- 9332.99
- Zydus Wellness
- 1396.7
- 0
- 0
- 1817.45
- 1363.85
- 8889.73
- Godrej Agrovet
- 446.65
- 0.5
- 0.11
- 592.8
- 441
- 8595.36
- CCL Products India
- 569.05
- 5.75
- 1.02
- 579.2
- 315.6
- 7569.95
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- KRBL
- 20.39
- 2.31
- 17.01
- 12.57
- Eid Parry India
- 10.29
- 1.75
- 12.23
- 4.84
- Zydus Wellness
- 28.78
- 1.84
- 5.89
- 12.52
- Godrej Agrovet
- 20.54
- 3.57
- 17.48
- 5.11
- CCL Products India
- 37.04
- 6.05
- 18.87
- 14.11
Shareholding
- Category
- Percentage
- No. of shares
- Public Shareholding
- 34.65%
- 22,045,464
- Threpsi Care Llp
- 11.35%
- 7,220,216
- Others
- 0.11%
- 71,975
- Icici Prudential Value Discovery Fund
- 3.73%
- 2,371,511
- Nippon Life India Trustee Ltd-A/C Nippon India Small Cap Fund
- 3.48%
- 2,214,852
- Others
- 2.23%
- 1,425,385
- Others
- 4.59%
- 2,923,234
- Government Pension Fund Global
- 1.58%
- 1,003,142
- Others
- 2.25%
- 1,433,384
- Lici Asm Non Par
- 2.02%
- 1,283,643
- Others
- 0.41%
- 269,771
- Others
- 1.7%
- 1,082,046
- Others
- 0.46%
- 295,120
- Others
- 0.35%
- 223,068
- HUF
- 0.16%
- 101,471
- Unclaimed or Suspense or Escrow Account
- 0.02%
- 9,973
- LLP
- 0.01%
- 4,704
- Clearing Members
- 0%
- 1,150
- Naval Group Insurance Fund
- 0%
- 819
- Trusts
- 0%
- 558
- Others
- 0.14%
- 88,821
- Others
- 0.02%
- 13,624
- Others
- 0.01%
- 3,946
- Others
- 0%
- 2,330
- Others
- 0%
- 688
- Others
- 0%
- 27
- Others
- 0%
- 6
- Promoter & Promoter Group Shareholding
- 65.35%
- 41,586,680
- Zydus Lifesciences Limited
- 57.59%
- 36,647,509
- Zydus Family Trust(Trustee:Mr. Pankaj R. Patel,Smt. Pritiben P. Patel, Dr. Sharvil P. Patel)
- 7.75%
- 4,933,734
- Pripan Investment Private Limited
- 0%
- 640
- Pankaj Ramanbhai Patel(Taraben Patel Family Will Trust, TrusteeMr Pankaj R Patel Dr Sharvil P Patel)
- 0%
- 533
- Pankajbhai Ramanbhai Patel
- 0%
- 1,599
- Pankajbhai Ramanbhai Patel(HUF,Karta:Mr. Pankaj R. Patel)
- 0%
- 1,066
- Pritiben Pankajbhai Patel
- 0%
- 533
- Sharvil Pankajbhai Patel
- 0%
- 533
- Shivani Pankajbhai Patel
- 0%
- 533
Shareholding Pattern
Shareholding Trend
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 02-Feb-23
- Quarterly Results
- 10-Nov-22
- Quarterly Results
- 29-Jul-22
- Quarterly Results
- 17-May-22
- Audited Results & Final Dividend
- 02-Feb-22
- Quarterly Results
- 28-Oct-21
- Quarterly Results
- 30-Jul-21
- Quarterly Results
- 10-May-21
- Audited Results & Final Dividend
- 01-Feb-21
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 29-Jul-22
- 17-May-22
- AGM
- 30-Jul-21
- 10-May-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 17-May-22
- 15-Jul-22
- 14-Jul-22
- 5
- 10-May-21
- -
- 14-Jul-21
- 5
Company Profile
ABOUT Zydus Wellness
- Industry Food Processing
- ISIN INE768C01010
- BSE Code 531335
- NSE Code ZYDUSWELL
Zydus Wellness Limited is an India-based consumer wellness company. The Company operates as an integrated consumer company with business encompassing the entire value chain in the development, production, marketing and distribution of health and wellness products. The product portfolio of the Company includes brands, such as Everyuth, Nutralite, Complan, Glucon-D, Sugarlite, Everyuth, Nycil and Sugar Free D’lite. Complan is a health food drink, scientifically designed for growing school children and contains nutrients along with milk protein. Sugar Free is a low-calorie sweetener, which is a replacement of sugar for the calorie-conscious, weight watchers and diabetics. Glucon-D is a glucose powder, which is available in various flavors variants with Vitamin D and Vitamin C. Everyuth offers a range of skincare products under the brand name of Everyuth Naturals. Nycil prickly heat and cooling powder brand and has also expanded portfolio into hand sanitizer category.
MANAGEMENT
- Tarun Arora Chief Executive Officer, Whole Time Director
- Umesh Parikh Chief Financial Officer
- Nandish Joshi Company Secretary, Compliance Officer
Company Summary
ZYDUS WELLNESS SUMMARY
Zydus Wellness is trading 0.00% lower at Rs 1396.70 as compared to its last closing price. Zydus Wellness has been trading in the price range of 1415.95 & 1392.05. Zydus Wellness has given -7.28% in this year & -3.24% in the last 5 days.
Zydus Wellness has TTM P/E ratio 32.14 as compared to the sector P/E of 18.66. There are 8 analysts who have initiated coverage on Zydus Wellness. There are 5 analysts who have given it a strong buy rating & 3 analysts have given it a buy rating. 0 analysts have given the stock a sell rating.
The company posted a net profit of 19.56 Crores in its last quarter.
Listed peers of Zydus Wellness include KRBL (0.49%), Eid Parry India (-1.98%), Zydus Wellness (0%) etc.
Zydus Wellness has a 65.35% promoter holding & 34.65% public holding.
FAQs about Zydus Wellness
- 0 analysts have given a strong sell rating
- 0 analysts have given a sell rating
- 0 analysts have given a hold rating
- 3 analysts have given a buy rating
- 5 analysts have given a strong buy rating
- TTM P/E: 32.14
- Sector P/E: 18.66
- Dividend Yield: 0.36%
- D/E ratio: -